IONS Earnings Date: Nov 4, 2026 (Estimated) — Ionis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is IONS's next earnings date?
Ionis Pharmaceuticals, Inc. (IONS) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.22 on revenue of $181.6M.
How did IONS do in its last earnings report?
In its most recent report on Jul 29, 2026 (Q2 2026), Ionis Pharmaceuticals, Inc. posted EPS of -$0.42 versus the -$0.95 estimate, a beat of 55.8%. Revenue was $268.0M against a $189.6M estimate. The stock's 1-day post-earnings move was -2.3%.
How much does IONS stock move after earnings?
IONS beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.8% (up or down) in the day after earnings.
About Ionis Pharmaceuticals, Inc.
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-29 | Q2 2026 | -0.95 | -0.42 | +55.79% | $268.0M | ✅ Beat | -2.28% | -0.42% | +14.57% |
| 2026-04-29 | Q1 2026 | -0.80 | -0.30 | +62.50% | $246.0M | ✅ Beat | +4.25% | +4.83% | +7.73% |
| 2026-02-25 | Q4 2025 | -1.26 | -1.15 | +8.73% | $203.0M | ✅ Beat | -5.29% | -7.95% | -14.92% |
| 2025-10-29 | Q3 2025 | -1.12 | -0.61 | +45.27% | $157.0M | ✅ Beat | -2.30% | -0.94% | +12.41% |
| 2025-07-30 | Q2 2025 | 0.16 | 0.85 | +431.25% | $452.0M | ✅ Beat | +4.56% | +3.79% | +3.06% |
| 2025-04-30 | Q1 2025 | -1.03 | -0.93 | +9.71% | $132.0M | ✅ Beat | +3.02% | +6.88% | +12.24% |
| 2025-02-19 | Q4 2024 | -0.84 | -0.43 | +48.81% | $227.0M | ✅ Beat | -0.44% | -0.31% | +4.35% |
| 2024-11-06 | Q3 2024 | -1.16 | -0.72 | +37.93% | $134.0M | ✅ Beat | +0.62% | -2.65% | -5.28% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $225.7M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Commercial Member | 52.6% | $118.6M | +15.4% | — | — | $102.8M | $115.6M |
| Royalty | 33.7% | $76.0M | +8.6% | — | $64.2M | $70.0M | $75.7M |
| Product | 13.8% | $31.1M | +61.6% | $17.1M | — | $19.3M | $31.8M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.